Aminocarboxylic acid derivative and medicinal use thereof
The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.
1. 1-[(6-{[2,4-bis(trifluoromethyl)benzyl]oxy}-1-methyl-3,4-dihydro-2-naphthalenyl)methyl]-3-azetidinecarboxylic acid, a salt thereof, an N-oxide form thereof, a solvate thereof or a prodrug thereof.
2. The compound according to claim 1 , which is selected from the group consisting of
(1) 1-[(6-{[2,4-bis (trifluoromethyl)benzyl] oxy } -1-methyl-3,4-dihydro-2-naphthalenyl)methyl]-3-azetidinecarboxylic acid,
(2) ethyl 1-[(6-{[2,4-bis(trifluoromethyl)benzyl]oxy}-1-methyl-3,4-dihydro-2-naphthalenyl)methyl]-3-azetidinecarboxylate,
(3) 1-[(6-{[2,4-bis (trifluoromethyl)benzyl] oxy } -1-methyl-3,4-dihydro-2-naphthalenyl)methyl]-3-azetidinecarboxylic acid monohydrate,
(4) 1-[(6-{[2,4-bis (trifluoromethyl)benzyl] oxy } -1-methyl-3,4-dihydro-2-naphthalenyl)methyl]-3-azetidinecarboxylic acid hydrochloride,
(5) sodium 1-[(6-{[2,4-bis (trifluoromethyl)benzyl] oxy } -1-methyl-3,4-dihydro-2-naphthalenyl)methyl]-3-azetidinecarboxylate, and
(6) potassium 1-[(6-{[2,4-bis(trifluoromethyl)benzyl] oxy}-1-methyl-3,4-dihydro-2-naphthalenyl)methyl] -3-azetidinecarboxylate.
3. A compound which is 1-[(6-{[2,4-bis(trifluoromethyl)benzyl] oxy}-1-methyl-3,4-dihydro-2-naphthalenyl)methyl]-3-azetidinecarboxylic acid.
4. A pharmaceutical composition which comprises the compound according to claim 1 , a salt thereof, an N-oxide form thereof, a solvate thereof or a prodrug thereof.